Arax Advisory Partners’s Dr. Reddy's Laboratories RDY Stock Holding History

Arax Advisory Partners’s Portfolio RDY Stock Details RDY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$44.7K	Sell	3,228 -8,923	-73%	-$124K	﹤0.01%	1736
2025 Q4	$171K	Buy	12,151 +10,678	+725%	+$150K	0.01%	1103
2025 Q3	$20.6K	Buy	1,473 +558	+61%	+$8.03K	﹤0.01%	2252
2025 Q2	$25.1K	Buy	915 +540	+144%	+$7.71K	﹤0.01%	1555
2025 Q1	$4.95K	Buy	+375	New	+$5.17K	﹤0.01%	1781
2018 Q3	–	Sell	-535	Closed	-$3K	–	708
2018 Q2	$3K	Sell	535 -350	-40%	-$2.21K	﹤0.01%	425
2018 Q1	$5K	Buy	885 +145	+20%	+$1.02K	﹤0.01%	378
2017 Q4	$5K	Buy	740 +360	+95%	+$2.59K	﹤0.01%	378
2017 Q3	$2K	Buy	380 +35	+10%	+$252	﹤0.01%	425
2017 Q2	$3K	Sell	345 -360	-51%	-$2.93K	﹤0.01%	424
2017 Q1	$5K	Sell	705 -550	-44%	-$4.75K	﹤0.01%	360
2016 Q4	$11K	Buy	+1,255	New	+$11.7K	0.01%	316

Other funds holding RDY

Robeco Institutional Asset Management Rotterdam, Netherlands $70.2B AUM 29.99% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

AIM

Aikya Investment Management London, United Kingdom $345M AUM 10.59% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Arax Advisory Partners's RDY Position: Q1 2026 in Review

Arax Advisory Partners reduced its Dr. Reddy's Laboratories (RDY) stake by 73% in Q1 2026, selling an estimated $124K and leaving 3,228 shares worth $44.7K. The position accounts for ﹤0.01% of the portfolio, ranked #1736.

Arax Advisory Partners first reported a position in RDY in Q4 2016 and has held it in 12 quarters since. The position peaked at $171K in Q4 2025. 247 funds tracked by Wall St. Rank hold RDY as of Q1 2026.

Arax Advisory Partners held 3,228 shares of Dr. Reddy's Laboratories worth $44.7K as of Q1 2026.
Arax Advisory Partners sold 8,923 Dr. Reddy's Laboratories shares in Q1 2026, an estimated $124K.
Dr. Reddy's Laboratories made up ﹤0.01% of Arax Advisory Partners's portfolio in Q1 2026, its #1736 holding.
Arax Advisory Partners first reported a position in Dr. Reddy's Laboratories in Q4 2016 and has held it in 12 quarters since.
Arax Advisory Partners's Dr. Reddy's Laboratories position peaked at $171K in Q4 2025.
247 funds tracked by Wall St. Rank held Dr. Reddy's Laboratories as of Q1 2026.

Based on Arax Advisory Partners's 13F filing for Q1 2026, filed 13 May 2026.